Chief Scientific Officer · Cartesian Therapeutics, Inc. (RNAC)

Takashi Kishimoto

A named executive officer of Cartesian Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$1,306,675

Salary $399,798Stock awards $214,133

FY2020: $807,333

4th of 7 named executive officers at Cartesian Therapeutics by FY2021 total.

7 named officers on file for Cartesian Therapeutics, FY2021

Takashi Kishimoto’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 3 equity grants, each cited to its filing
  • RNAC’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Cartesian Therapeutics’s whole pay program stands against its peers

  • Cartesian Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RNAC→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 3, 2022 (DEF 14A).

Free

Get Takashi Kishimoto’s full pay file as a PDF — free

More than this page: up to 10 years of Takashi’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Takashi Kishimoto compensation by year

Cartesian Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Cartesian Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021
Salary$386,703$399,798
Bonus$0$0
Stock awards$0$214,133
Option awards$237,063$526,588
Non-equity incentive$177,949$160,000
Pension and deferred compensation$0$0
All other$5,618$6,156
Total$807,333$1,306,675

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Cartesian Therapeutics, Inc. DEF 14A filed May 3, 2022, accession 0001453687-22-000071, and prior-year filings.

How this page was built: the Cartesian Therapeutics, Inc. filed document, accession 0001453687-22-000071. Every figure is read from that document and cited to the page and table it appears in. Filed May 3, 2022.

$807K
$1.3M
FY20
FY21
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU38,000$123,880—
Option27,082—$2.60
Option230,000—$2.99
Option72,916—$2.30

Per the Outstanding Equity Awards at Fiscal Year-End table in Cartesian Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Cartesian Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Carsten BrunnPresident and Chief Executive Officer$3,671,395
Kevin TanChief Financial Officer$2,601,622
Peter TraberChief Medical Officer$1,600,685
Takashi Kishimoto · this pageChief Scientific Officer$1,306,675
Lloyd JohnstonChief Operations Officer$1,304,845
Bradford DahmsChief Financial Officer$868,053
Ann DonohueVP, Finance and Corporate Controller, Principal Financial and Accounting Officer$361,493

The full Cartesian Therapeutics compensation record

free company brief

This page is one person within Cartesian Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Cartesian Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Cartesian Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Takashi Kishimoto's compensation dossier · One-time report. No refunds.